Fresenius Medical Care shares drop on U.S. dialysis payment adjustment
Reuters
Published Jun 27, 2023 04:51AM ET
By Ludwig Burger
FRANKFURT (Reuters) -Shares in kidney dialysis group Fresenius Medical Care (NYSE:FMS) fell as much as 5% on Tuesday after a payment increase proposed by a major U.S. public health insurance body fell short of market expectations.
Analysts said the base-rate payment increase of 1.6%, proposed for 2024 by the Centers for Medicare & Medicaid Services (CMS) late on Monday, fell short of the 3% to 4% projected by the market.
"This further increases the challenge to meet 2025 targets as further savings may be required," Jefferies analysts said in a note.
Fresenius Medical, the world's largest provider of blood-cleansing treatments, is cutting costs and seeking to sell non-core businesses after U.S. staff shortages and cost inflation hit its earnings hard last year, compounding an existing burden from a high COVID-19-mortality rate among its patients.
This has also weighed on the performance of its parent Fresenius SE (ETR:FREG), triggering the healthcare group's decision to give up strategic control of Fresenius Medical.
Fresenius Medical shares were down 4% at 0814 GMT, erasing gains over the past three trading sessions.
The Germany-based company said it would assess the proposal and provide feedback to CMS within the 60-day deadline.
"Generally speaking, we have only assumed a moderate increase in Medicare payments for our 2025 margin targets," it said in a statement.
The group is targeting a 2025 operating income margin over sales of 10% to 14% in 2025, up from 7.9% in 2022.
CMS regulates U.S. government coverage of dialysis services for people with kidney failure, accounting for about 35% of Fresenius Medical's group sales, according to analysts at Credit Suisse.
The analysts added that the final decision on payment adjustments tend to be slightly more favourable for dialysis providers. The company said the final rate decisions was expected in the autumn.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.